{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:29:16Z","timestamp":1778048956724,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,10,24]],"date-time":"2008-10-24T00:00:00Z","timestamp":1224806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:p>Non\u2010muscle\u2010invasive bladder cancers form a heterogeneous group of tumours with varying recurrence and progression rates. Recently low\u2010, intermediate\u2010 and high\u2010risk categories, based on tumour stage and grade, have been used to predict prognosis and guide treatment. Whilst the therapeutic options for the low\u2010 and high\u2010risk groups are well defined, the optimal treatment for patients in the intermediate\u2010risk group is unknown. We review current treatment options, recent advances and future developments in the treatment of patients with intermediate\u2010risk non\u2010muscle\u2010invasive bladder cancer.<\/jats:p>","DOI":"10.1111\/j.1464-410x.2008.08094.x","type":"journal-article","created":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T10:59:30Z","timestamp":1235386770000},"page":"726-729","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Therapeutic options in the management of intermediate\u2010risk nonmuscle\u2010invasive bladder cancer"],"prefix":"10.1111","volume":"103","author":[{"given":"Andras","family":"Horvath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugh","family":"Mostafid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,23]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199707000-00017"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(61)90304-X"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0022-5347(17)39544-7","article-title":"The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2)","volume":"144","author":"Malkowicz SB","year":"1990","journal-title":"J Urol"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000125486.92260.b2"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6923.257"},{"key":"e_1_2_7_10_2","unstructured":"EAU.Guidelines on TaT1 (Non\u2010Muscle Invasive) Bladder Cancer. Available at:http:\/\/www.uroweb.org\/fileadmin\/user_upload\/guidelines\/tat1%20bladder%20cancer.pdf. Accessed April 2008"},{"key":"e_1_2_7_11_2","unstructured":"BAUS (Multi\u2010disciplinary Team).Guidance for Managing Bladder Cancer. Available at:http:\/\/www.bauslibrary.co.uk\/pdfs\/bsonc\/mdt%20guidance%20for%20bladder%20cancer.pdf. Accessed April 2008"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.09.003"},{"key":"e_1_2_7_13_2","first-page":"157","volume-title":"Bladder Tumors","author":"Oosterlinck W","year":"2006"},{"key":"e_1_2_7_14_2","volume-title":"Summary of Product Characteristics. Mitomycin\u2010C Kyowa","author":"Kyowa Hakko."},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.02.063"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.8.597"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.10.006"},{"key":"e_1_2_7_18_2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0022-5347(18)31767-1","article-title":"Maintenance intravesical BCG therapy for superficial bladder tumours: 3\u2003week multiple courses versus monthly doses","volume":"177","author":"Ali\u2010El\u2010Dein B","year":"2007","journal-title":"J Urol"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.04.104"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70472-1"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07314.x"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2008.08094.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2008.08094.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:09:15Z","timestamp":1761732555000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2008.08094.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,23]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1464-410X.2008.08094.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2008.08094.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,23]]},"assertion":[{"value":"2009-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}